<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel rdf:about="http://repository.usmf.md:80/xmlui/handle/20.500.12710/24177">
<title>Revista de Științe ale Sănătății din Moldova : Moldovan Journal of Health Sciences 2022 nr. 3(29)</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/24177</link>
<description/>
<items>
<rdf:Seq>
<rdf:li rdf:resource="http://repository.usmf.md:80/xmlui/handle/20.500.12710/24207"/>
<rdf:li rdf:resource="http://repository.usmf.md:80/xmlui/handle/20.500.12710/24206"/>
<rdf:li rdf:resource="http://repository.usmf.md:80/xmlui/handle/20.500.12710/24204"/>
<rdf:li rdf:resource="http://repository.usmf.md:80/xmlui/handle/20.500.12710/24202"/>
</rdf:Seq>
</items>
<dc:date>2026-04-26T13:41:17Z</dc:date>
</channel>
<item rdf:about="http://repository.usmf.md:80/xmlui/handle/20.500.12710/24207">
<title>Revista de Științe ale Sănătății din Moldova = Moldovan Journal of Health Sciences. 2022, Vol. 29(3)</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/24207</link>
<description>Revista de Științe ale Sănătății din Moldova = Moldovan Journal of Health Sciences. 2022, Vol. 29(3)
Revista de Științe ale Sănătății din Moldova (Moldovan Journal of Health Sciences) a fost lansată în octombrie 2014. Aceasta este editată în limbile română și engleză, conform standardelor și ghidurilor internaționale actuale în domeniul științelor medicale, și are o apariție trimestrială. Revista este înregistrată în Instrumentul Bibliometric Național IBN/IDSI (nr.1 din 16.11.2015), iar din 21 decembrie 2017, prin Hotărârea Consiliului Suprem pentru Știință și Dezvoltare Tehnologică nr. 169, a fost inclusă în lista revistelor științifice de Tip B. Revista este înregistrată în 2 baze de date internaționale.
</description>
<dc:date>2022-01-01T00:00:00Z</dc:date>
</item>
<item rdf:about="http://repository.usmf.md:80/xmlui/handle/20.500.12710/24206">
<title>Recovery of patients with gout</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/24206</link>
<description>Recovery of patients with gout
Rotaru, Larisa; Groppa, Liliana; Popa, Serghei; Nurseitova, Tamilla; Cornea, Cornelia
Abstract.&#13;
Introduction. The incidence and prevalence of gout&#13;
have increased worldwide in recent decades. Scientists at&#13;
the Rochester Epidemiology Project (MN, USA) have seen a&#13;
two-fold increase in the incidence of primary gout (patients&#13;
without diuretic exposure) over a 20-year period, which ended in 1996. The increase of incidence may be related due to&#13;
the difficulty and often unsatisfactory treatment options. The&#13;
aim of the study was to systematize the recommendations on&#13;
dietary treatment, and medication for patients with gout.&#13;
Materials and methods. An analytical, qualitative, and&#13;
secondary study was performed in the form of a synthesis&#13;
article. 115 sources were identified and analyzed; from this&#13;
list, 44 sources were selected according to the impact score&#13;
during the publication period and according to the level of&#13;
recommendations.&#13;
Results. 44 articles were included. Most studies were&#13;
small, retrospective analyses performed in single centers, with concerns for bias. Eleven studies (including five&#13;
randomized controlled trials) reported improved patient&#13;
outcomes following pharmacological interventions with&#13;
known efficacy in gout, including allopurinol, prednisolone,&#13;
NSAIDs and anakinra. Eight studies reported improved outcomes associated with non-pharmacological interventions:&#13;
inpatient rheumatology consultation and a hospital gout&#13;
management protocol. No studies to date have prospectively evaluated strategies designed to prevent re-admissions of&#13;
patients hospitalized for gout flares.&#13;
Conclusions. Urate crystals is completely soluble when&#13;
we can lower the serum level of uric acid to normal values,&#13;
but this often requires long-term treatment. The early onset&#13;
of rehabilitation of affected joints helps to reduce the articular inflammatory process, the pain syndrome and it delays&#13;
the progression of the underlying pathology while improving the quality of life in patients with gout. Further research&#13;
is needed to enable healthcare providers to individualize&#13;
and optimize gout treatment strategies, ensuring that patients with gout receive effective, safe, and high-quality care.
</description>
<dc:date>2022-01-01T00:00:00Z</dc:date>
</item>
<item rdf:about="http://repository.usmf.md:80/xmlui/handle/20.500.12710/24204">
<title>Impact of vitamin D in chronic kidney disease and its effect on the musculoskeletal system</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/24204</link>
<description>Impact of vitamin D in chronic kidney disease and its effect on the musculoskeletal system
Groza, Costina; Groppa, Liliana; Popa, Serghei; Sasu, Dorian; Rotaru, Larisa
Abstract.&#13;
Introduction. Vitamin D plays an important role in&#13;
maintaining musculoskeletal health. As the glomerular filtration rate decreases, vitamin D deficiency also occurs. The&#13;
aim of this paper is to highlight the level of vitamin D depending on the stage of chronic kidney disease.&#13;
Materials and methods. A structured search was performed in the PubMed, Scopus and HINARI databases,&#13;
where the relevant articles have been taken into account,&#13;
published in the last 20 years. The search terms used (in&#13;
English) were: „vitamin D deficiency”, „pathogenesis of vitamin D”, ”the impact of vitamin D in chronic kidney disease”,&#13;
„chronic kidney disease”.&#13;
Results. Several studies have shown that the change in&#13;
vitamin D levels is dependent to the decrease of glomerular&#13;
filtration rate. The lowest serum vitamin D concentration&#13;
was observed in stage 5 of chronic kidney disease. Vitamin D deficiency occurs due to a decrease in the number of&#13;
nephrons and a decrease in the number of proximal tubular&#13;
cells that absorb vitamin D (25 (OH) D) to be subsequently&#13;
hydroxylated to its active form by 1α-hydroxylase.&#13;
Conclusions. Patients with vitamin D-deficient due to&#13;
chronic kidney disease have an increased risk of decreased&#13;
bone mineral density and multiple fractures.
</description>
<dc:date>2022-01-01T00:00:00Z</dc:date>
</item>
<item rdf:about="http://repository.usmf.md:80/xmlui/handle/20.500.12710/24202">
<title>Molecular and cellular biomarkers in status epilepticus and epilepsy</title>
<link>http://repository.usmf.md:80/xmlui/handle/20.500.12710/24202</link>
<description>Molecular and cellular biomarkers in status epilepticus and epilepsy
Calcîi, Cornelia; Hadjiu, Svetlana; Calistru, Iulia; Calistru, Andrei; Feghiu, Ludmila; Constantin, Olga; Groppa, Stanislav
Summary.&#13;
Introduction. Peripheral biomarkers have numerous&#13;
uses in the treatment, prognosis, and pharmacovigilance&#13;
of epilepsy. Unfortunately, no peripheral biomarker has&#13;
demonstrated proven efficacy, although several options&#13;
are being investigated. In this article, we want to analyze&#13;
the main areas in which peripheral biomarkers can present their usefulness, including participation in the processes of inflammation, dysfunction of the blood-brain&#13;
barrier, changes in metabolism, hormones, and growth&#13;
factors.&#13;
Material and methods. Publications on diagnostic biomarkers of epilepsy were reviewed. References were identified by PubMed, MEDLINE and Scopus search until June&#13;
2022, with various combinations of the terms – „epilepsy”,&#13;
„seizures”, „epileptogenesis”, „biomarkers”, „neuroimaging”,&#13;
„inflammation”, „status epilepticus”, „prognosis”. A qualitative and analytical study was performed focused on primary studies published in 2020-2022. More than 85 sources&#13;
were identified and 33 were selected for analysis from the&#13;
PubMed, MEDLINE, and Scopus online databases. 12 articles, 5 clinical trials, 2 meta-analyses, 7 reviews, and 7 systematic reviews were identified.&#13;
Results. Screening articles from online databases according to the search criteria, we found 258 titles on molecular and cellular biomarkers in epilepsy highlighted.&#13;
The final bibliography included 33 sources that summarized that biomarkers of epileptogenesis are expensive&#13;
and difficult to research, but the identification of biomarkers specific to the entire epileptogenic process, in close&#13;
proximity to neuronal damage, have demonstrated the&#13;
possibility of predicting the risk of seizures, epilepsy and&#13;
resistance to treatment.&#13;
Conclusions. Epilepsy remains a continuous area of research; a special role is occupied by specific biomarkers of&#13;
great clinical importance, being necessary for the prognosis&#13;
of the disease, the risk of neurological sequelae, refractory&#13;
to anti-epileptic drugs. Thus, their identification could have&#13;
a significant impact on the clinical course of the disease.
</description>
<dc:date>2022-01-01T00:00:00Z</dc:date>
</item>
</rdf:RDF>
